ProfileGDS5678 / 1459225_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 75% 75% 72% 75% 78% 79% 75% 78% 75% 75% 74% 77% 75% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.9998876
GSM967853U87-EV human glioblastoma xenograft - Control 24.9397175
GSM967854U87-EV human glioblastoma xenograft - Control 34.9899575
GSM967855U87-EV human glioblastoma xenograft - Control 44.7025972
GSM967856U87-EV human glioblastoma xenograft - Control 54.9160675
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.2282378
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.4024979
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.9639175
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.3466878
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.9733975
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.9766475
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.8599174
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.1889177
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.9749375